免疫毒素市场－全球产业规模、份额、趋势、机会、预测：按产品、应用、最终用户、地区和竞争对手划分，2021-2031年

全球免疫毒素市场预计将从 2025 年的 1.7886 亿美元成长到 2031 年的 2.9358 亿美元，复合年增长率为 8.61%。

免疫毒素是透过将目标分子（例如配体或单株抗体）与强效的细菌或植物来源毒素结合而製成的人工嵌合体蛋白，旨在选择性地结合併摧毁病变细胞。该市场的主要成长要素是全球癌症发生率的不断上升，以及与全身化疗相比，对非标靶毒性较低的精准肿瘤疗法的需求日益增长。同时，重组DNA技术的进步使得免疫抗原性较低的结构得以实现，并拓宽了治疗窗口。根据美国癌症协会预测，到2025年，美国预计将新增约66,890例白血病病例，这凸显了对骨髓恶性肿瘤（这些药物通常针对的肿瘤）进行有效干预的迫切需求。

儘管前景乐观，但市场在安全性方面仍面临许多挑战，尤其是血管渗漏症候群的风险。这种严重的不利事件会导致毛细血管渗漏液体，使患者治疗更加复杂，并需要限制最大耐受剂量。此类毒性问题可能会阻碍监管核准流程，并限制免疫毒素疗法的更广泛商业性应用。

市场驱动因素

癌症和骨髓恶性肿瘤发生率的上升是全球免疫毒素市场的主要驱动力，也因此迫切需要能够清除抗药性细胞的强效生物疗法。随着全球发病率的不断攀升，医疗卫生系统正优先考虑引入比传统疗法疗效更优的标靶治疗。国际癌症研究机构（IARC）也支持这一趋势。该机构2024年2月发布的《全球癌症负担预测》报告显示，2022年全球新增癌症病例预计将达到2000万例，凸显了日益加重的疾病负担，亟需更先进的干预措施。大量公共资金正投入癌症研究，以促进免疫毒素等新型治疗方法的研发。例如，美国国家癌症研究所（NCI）已获得72.2亿美元的预算，用于支持广泛的癌症研究和人才培养，从而为下一代蛋白质疗法的研发创造有利环境。

随着生物製药公司成功推进新型免疫毒素结构进入后期临床试验，不断扩展的临床研发管线和监管核准正在进一步加速市场成长。研发人员正利用重组DNA技术设计稳定性较高、免疫抗原性较低的结构，进而直接解决血管渗漏症候群等传统安全障碍。 2024年6月，Medicenna Therapeutics宣布了一项重大的临床突破。在ASCO年会上，免疫毒素Visaxofusp在復发性胶质母细胞瘤患者中显示出13.5个月的中位总存活期，与对照组相比增加了88%。这些成功案例展现了免疫毒素的治疗潜力，刺激了持续的投资，并为快速获得商业化审批铺平了道路。

市场挑战

血管突触症候群 (VAS) 的风险仍然是全球免疫毒素市场商业性扩张的主要障碍。这种严重的不利事件通常需要严格的剂量限制，导致治疗药物无法达到有效清除大肿瘤所需的最佳浓度。因此，製药开发商面临更严格的监管审查和更长的临床试验週期，使得证明其具有良好的风险效益比变得越来越困难。这些安全隐患通常限制了免疫毒素的应用，使其只能作为三线或挽救性治疗而非一线疗法，从而显着缩小了目标患者群体，并降低了投资者对后期开发平臺候选药物的信心。

这种毒性限制直接阻碍了免疫毒素在发病率高的适应症领域的市场渗透，而这些适应症的潜在影响可能非常显着。儘管免疫毒素正被积极研究用于治疗非何杰金氏淋巴瘤等血液系统癌症，但安全障碍阻碍了其广泛应用。根据美国癌症协会预测，到2025年，美国预计将新增约80,350例非何杰金氏淋巴瘤病例。由于血管突触综合征等风险，无法安全地将免疫毒素应用于如此庞大的患者群体，这有效地限制了其收入潜力，并降低了这些生物疗法的整体普及率。

市场趋势

由于免疫毒素在固态肿瘤治疗领域的应用不断扩展，全球免疫毒素市场正经历重组。免疫毒素传统上在骨髓恶性肿瘤中取得了成功，但其治疗范围正在扩大，涵盖了造口等难治性疾病。研发人员正优先推动采用直接递送系统的后期临床项目，以避免细菌毒素相关的全身毒性。这项策略转变体现在大量资源投入临床实验註册研究中，检验免疫毒素在固态组织环境中的疗效。例如，Medicenna Therapeutics在2025年8月发布的第一季财报中披露，其拥有2050万美元的现金余额，用于积极支持其旗舰免疫毒素Visaxofusp（用于治疗復发性胶质母细胞瘤）的合作活动和III期临床试验准备工作。

同时，将人工智慧融入免疫毒素的设计和製备正成为解决免疫抗原性和脱靶结合等长期难题的关键趋势。透过利用机器学习演算法，研究人员能够以前所未有的精度预测蛋白质结构并优化抗体-毒素介面，从而加速建构具有更高安全性的新一代免疫毒素。如同2025年11月《化学世界》报导发表的题为「人工智慧设计的抗体以原子级精度标靶化抗原」的文章中所指出的，一种利用射频扩散模型的新型人工智慧引导製程已成功产生能够以原子级精度结合特定抗原位点的抗体。这项技术突破有望加速开发高特异性、低免疫抗原性的免疫毒素有效载荷。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球免疫毒素市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（白喉毒素、炭疽菌毒素、绿脓桿菌外毒素等）
  • 依应用领域（生物医学研究、治疗方法开发）
  • 按最终用户（製药和生物技术公司、合约研究组织/合约生产组织、学术和研究机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美免疫毒素市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲免疫毒素市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区免疫毒素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲免疫毒素市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲免疫毒素市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球免疫毒素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Creative Biolabs, Inc.
• List Biological Labs, Inc.
• The Native Antigen Company
• Bio-Techne Corporation
• Abcam Limited
• Cayman Chemical Company
• Merck KGaA
• Enzo Biochem Inc.
• Santa Cruz Biotechnology In
• Quadratech Diagnostics Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Immunotoxins Market is projected to expand from USD 178.86 Million in 2025 to USD 293.58 Million by 2031, reflecting a CAGR of 8.61%. Immunotoxins are engineered chimeric proteins that combine a targeting moiety, such as a ligand or monoclonal antibody, with a potent bacterial or plant-derived toxin intended to selectively bind to and destroy diseased cells. The market is primarily driven by the increasing global incidence of cancer and the growing demand for precision oncology treatments that offer reduced off-target toxicity compared to systemic chemotherapy, while advancements in recombinant DNA technology are enabling the creation of less immunogenic constructs with improved therapeutic windows. According to the American Cancer Society, approximately 66,890 new cases of leukemia are expected to be diagnosed in the United States in 2025, highlighting the critical need for effective interventions in hematological malignancies that these agents frequently target.

Despite this positive outlook, the market encounters a significant obstacle regarding safety, particularly the risk of vascular leak syndrome. This severe adverse event involves fluid leakage from capillaries, which complicates patient management and necessitates limits on the maximum tolerated dose. Such toxicity issues can impede regulatory approval processes and restrict the broader commercial adoption of immunotoxin therapies.

Market Driver

The escalating prevalence of cancer and hematological malignancies serves as the primary catalyst for the Global Immunotoxins Market, generating urgent demand for potent biological therapies capable of eliminating resistant cells. As global incidence rates rise, healthcare systems are prioritizing the adoption of targeted agents that provide superior efficacy compared to conventional treatments. This trend is underscored by the International Agency for Research on Cancer (IARC), which reported in its 'Global Cancer Burden Estimates' in February 2024 that there were an estimated 20 million new cancer cases worldwide in 2022, emphasizing the increasing disease burden that requires advanced interventions. To facilitate the discovery of novel modalities like immunotoxins, substantial public funding is being directed toward oncology research; for instance, the National Cancer Institute received a consolidated budget of $7.22 billion in 2024 to support a wide range of cancer research and training, creating an environment favorable for developing next-generation protein-based therapeutics.

Market growth is further accelerated by the expansion of the clinical pipeline and regulatory approvals, as biopharmaceutical companies successfully advance novel immunotoxin constructs through late-stage trials. Developers are applying recombinant DNA technology to engineer constructs with enhanced stability and reduced immunogenicity, directly addressing historical safety barriers such as vascular leak syndrome. A significant clinical breakthrough was highlighted by Medicenna Therapeutics in June 2024; in results presented at ASCO, the immunotoxin Bizaxofusp demonstrated a median overall survival of 13.5 months in patients with recurrent glioblastoma, representing an 88% improvement over the external control arm. Such successes validate the therapeutic potential of immunotoxins, encouraging continued investment and paving the way for faster regulatory pathways to commercialization.

Market Challenge

The risk of vascular leak syndrome remains a primary impediment to the commercial expansion of the global immunotoxins market. This severe adverse event often requires strict limitations on dosage, preventing the therapeutic agent from reaching the optimal concentration necessary to effectively eradicate large tumor masses. Consequently, pharmaceutical developers encounter increased regulatory scrutiny and extended clinical trial timelines, as demonstrating a favorable risk-benefit ratio becomes increasingly difficult. These safety concerns frequently relegate immunotoxins to third-line or salvage settings rather than first-line treatments, which significantly reduces the addressable patient population and diminishes investor confidence in late-stage pipeline candidates.

This toxicity limitation directly hinders market penetration in high-incidence indications where these agents could otherwise have a major impact. While immunotoxins are heavily investigated for hematological cancers such as non-Hodgkin lymphoma, safety hurdles prevent their widespread deployment. According to the American Cancer Society, approximately 80,350 new cases of non-Hodgkin lymphoma are projected to be diagnosed in the United States in 2025. The inability to safely administer immunotoxins to this substantial patient base, due to risks like vascular leak syndrome, effectively caps revenue potential and slows the overall adoption rate of these biologic therapies.

Market Trends

The global immunotoxins market is being reshaped by an expansion into solid tumor therapeutic applications, shifting the modality beyond its traditional success in hematological malignancies toward difficult-to-treat indications such as glioblastoma. Developers are increasingly prioritizing late-stage clinical programs that utilize direct delivery systems to bypass the systemic toxicity often associated with bacterial toxins. This strategic pivot is demonstrated by significant resource allocation toward registrational trials designed to validate these agents in solid tissue environments. For example, Medicenna Therapeutics reported in its 'First Quarter Fiscal 2026 Financial Results' in August 2025 that the company held a cash balance of $20.5 million to actively support partnering efforts and the Phase 3 readiness of its lead immunotoxin, Bizaxofusp, for the treatment of recurrent glioblastoma.

Simultaneously, the integration of AI in immunotoxin design and discovery is emerging as a critical trend to address historical limitations regarding immunogenicity and off-target binding. By using machine learning algorithms, researchers can now predict protein structures and optimize antibody-toxin interfaces with unprecedented accuracy, facilitating the creation of next-generation constructs with improved safety profiles. As noted by Chemistry World in the November 2025 article 'AI-designed antibodies target antigens with atomic precision,' a new AI-guided process utilizing the RFdiffusion model successfully produced antibodies that bind to specific antigen sites with atomic-level precision, a technological breakthrough expected to accelerate the development of highly specific and less immunogenic immunotoxin payloads.

Key Market Players

• Creative Biolabs, Inc.
• List Biological Labs, Inc.
• The Native Antigen Company
• Bio-Techne Corporation
• Abcam Limited
• Cayman Chemical Company
• Merck KGaA
• Enzo Biochem Inc.
• Santa Cruz Biotechnology In
• Quadratech Diagnostics Ltd

Report Scope

In this report, the Global Immunotoxins Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunotoxins Market, By Product

• Diptheria Toxin
• Anthrax Based Toxins
• Pseudomonas Exotoxin
• Others

Immunotoxins Market, By Application

• Biomedical Research
• Therapy Development

Immunotoxins Market, By End User

• Pharmaceutical & Biotechnology Companies
• CROs & CMOs
• Academic & Research Institutes

Immunotoxins Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunotoxins Market.

Available Customizations:

Global Immunotoxins Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunotoxins Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Diptheria Toxin, Anthrax Based Toxins, Pseudomonas Exotoxin, Others)
  • 5.2.2. By Application (Biomedical Research, Therapy Development)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, CROs & CMOs, Academic & Research Institutes)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Immunotoxins Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunotoxins Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Immunotoxins Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Immunotoxins Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Immunotoxins Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunotoxins Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Immunotoxins Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Immunotoxins Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Immunotoxins Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Immunotoxins Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Immunotoxins Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunotoxins Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Immunotoxins Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Immunotoxins Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Immunotoxins Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Immunotoxins Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Immunotoxins Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunotoxins Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Immunotoxins Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Immunotoxins Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Immunotoxins Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunotoxins Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Immunotoxins Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Immunotoxins Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunotoxins Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Creative Biolabs, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. List Biological Labs, Inc.
• 15.3. The Native Antigen Company
• 15.4. Bio-Techne Corporation
• 15.5. Abcam Limited
• 15.6. Cayman Chemical Company
• 15.7. Merck KGaA
• 15.8. Enzo Biochem Inc.
• 15.9. Santa Cruz Biotechnology In
• 15.10. Quadratech Diagnostics Ltd

16. Strategic Recommendations

17. About Us & Disclaimer